



References

- 1- **Abrams D, Schulze-Neick I and Magee AG.(2000):** Sildenafil as a selective pulmonary vasodilator in childhood primary pulmonary hypertension. *Heart*; 84:E4.
- 2- **Abrams G, Nanda N and Dubovsky E.(1998):** Use of macroaggregated albumin lung perfusion scan to diagnose hepatopulmonary syndrome: a new approach. *Gastroenterology*; 114: 305-310.
- 3- **Abrams GA, and Fallon MB.(1998):** Treatment of hepatopulmonary syndrome with *Allium sativum* L. (garlic): a pilot trial. *J Clin Gastroenterol*; 27: 232–235.
- 4- **Abrams GA, Jaffe CC, Hoffer PB, Binder HJ, Fallon MB. et al.(1995):** Diagnostic utility of contrast echocardiography and lung perfusion scan in patients with hepatopulmonary syndrome. *Gastroenterology*;109:1283-1288.
- 5- **Agusti´ AGN, Roca J, Rodriguez-Roisin R, Mastai R, Wagner PD, Bosch J. et al.(1989):** Pulmonary hemo-dynamics and gas exchange during exercise in liver cirrhosis. *Am Rev Respir Dis*; 139: 485–491.
- 6- **Aller R, Moya JL, Moreira V. et al.(1999):** Diagnosis of hepatopulmonary syndrome with contrast transesophageal echocardiography: advantages over contrast transthoracic echocardiography. *Dig Dis Sci*;44:12438.



References

- 7- **Andrivet P, Cadranel J, Housset B, Herigault R, Harf A, Adnot S. et al.(1993):** Mechanisms of impaired arterial oxygenation in patient with liver cirrhosis and severe respiratory insufficiency. Effects of indomethacin. *Chest*; 103:500-507.
- 8- **Anel RM. and Sheagren JN.(2001):** Novel presentation and approach to management of hepatopulmonary syndrome with use of antimicrobial agents. *Clin Infect Dis*; 32: 131–136.
- 9- **Arguedas MR, Abrams GA, Krowka MJ, Fallon MB. et al.(2003):** Prospective evaluation of outcomes and predictors of mortality in patients with hepatopulmonary syndrome undergoing liver transplantation. *Hepatology*;37:192-197.
- 10- **Arguedas MR, Drake BB, Kapoor A, Fallon MB. et al.(2005):** Carboxyhemoglobin levels in cirrhotic patients with and without hepatopulmonary syndrome. *Gastroenterology*;128:328-333.
- 11- **Arguedas, MR .and Fallon, MB.(2005):** Hepatopulmonary Syndrome. *Clin Liver Dis*; 9: 733-746.
- 12- **Badesch D, Rubin L. in Pulmonary Hypertension by Fink M, Abraham E, Vincent JL, Kochanek P. et al.(2005):** Shoemaker textbook of critical care Publisher: Natasha Adjelkovic thired edition, pp. 631.
- 13- **Ballou DP, Zhao Y, Brandish PE, Marletta MA. et al.(2002):** Revisiting the kinetics of nitric oxide (NO) binding to soluble guanylate cyclase: The simple NO-binding model is incorrect.;99:12097–12101.



References

- 14- **Benítez C, Arrese M, Jorquera J, Godoy I, Contreras A, Loyola S, Domínguez P. et al.(2009):**Successful treatment of severe hepatopulmonary syndrome with a sequential use of TIPS placement and liver transplantation. *Annals of Hepatology*; 8:71-74.
- 15- **Benjaminov FS, M Prentice, Sniderman KW, Siu S, Liu P, Wong F. et al.(2003):**Portopulmonary hypertension in decompensated cirrhosis with refractory ascites. *Gut*;52:1355-1362.
- 16- **Boker KHW, Hoper M, Lehman M, Fabel H, Manns MP.et al.(1994):** Effect of nitric oxide synthase inhibitor L-NAME on vascular resistance and arterial oxygenation in patients with hepatopulmonary syndrome. *Hepatology*;20(Suppl): 333A.
- 17- **Cadranel J, Milleron B, Cadranel J-R, Fermand J-P, Andriuet P, Brouet J-C, Adnot S. et al.(1992):** Severe hypoxemia associated intrapulmonary shunt in a patient with chronic liver disease: improvement after medical treatment. *Am Rev Respir Dis*;146:526-527.
- 18- **Caldwell SH, Jeffers LJ, Narula OS, Lang EA, Reddy KR, Schiff ER. et al.(1992):** Ancient remedies revisited: does *Allium sativum* (garlic) palliate the hepatopulmonary syndrome? *J Clin Gastroenterology*;15:248-250.
- 19- **Callejas-Rubio JL, Salmeron-Escobar J, Gonzalez-Calvin J, Ortego-Centeno N. et al.(2006):** Successful treatment of severe portopulmonary hypertension in a patient with Child C cirrhosis by sildenafil. *Liver Transpl*; 12: 690-691.



References

- 20- **Cancado EL, Medeiros DM, Deguti MM et al.(2006):** Celiac disease associated with nodular regenerative hyperplasia, pulmonary abnormalities, and IgA anticardiolipin antibodies. *J Clin Gastroenterol*; 40:135-139.
- 21- **Chung RT and Podolsky DK.(2001):** cirrhosis and its complications In Braunwald E,Fauci AS and Kasper DL (eds): *Harrison's principles of internal medicine* 15th ed.Mc Graw-Hill; 1754-1767.
- 22- **Collisson EA, Nourmand H, Fraiman MH, et al. (2002):** Retrospective analysis of the results of liver transplantation for adults with severe hepatopulmonary syndrome. *Liver Transpl*; 8: 925–931.
- 23- **Cremona G, Higenbottam TW, Mayoral V.et al.(1995):** Elevated exhaled nitric oxide in patients with hepatopulmonary syndrome. *Eur Respir J*; 8: 1883–1885.
- 24- **Cris A. Meyer, Charles S. White, Kenneth E. et al.(2000):**Diseases of the Hepatopulmonary Axis. *RadioGraphics* 2000; 20:687–698.
- 25- **De Wolf AM, Gasior T, Kang Y. et al.(1991):** Pulmonary hypertension in a patient undergoing liver transplantation. *Transplant Proc*; 23: 2000–2001.
- 26- **De Wolf AM, Scott VL, Gasior T. et al.(1993) :**Pulmonary hypertension and liver transplantation. *Anesthesiology*;78:213–214.
- 27- **DeberaldiniM.ArcanjoAB.MeloE, daSilvaRF, FelcioHC Arroyo PC Jr, et al.(2008):** Hepatopulmonary syndrome: morbidity and survival after liver transplantation. *Transplant Proc*;40:3512-3516.



References

- 28- **Degano B, Mittaine M, Hervé P, Rami J, Kamar N, Suc B, et al.(2009):** Nitric oxide production by the alveolar compartment of the lungs in cirrhotic patients. *Eur Respir J*;34:138-144.
- 29- **Deibert P, Allgaier HP, Loesch S, Müller C, Olschewski M. et al.(2006):** Hepatopulmonary syndrome in patients with chronic liver disease: role of pulse oximetry. *Gastroenterology*, 6:15.
- 30- **Dickson ER, Murtaugh PA and Wiesner RH. et al.(1992):** Primary sclerosing cholangitis: refinement and validation of survival models. *Gastroenterology*; 103: 1893-1901.
- 31- **Dudzinski DM, Igarashi J, Greif D, Michel T. et al.(2006):** The regulation and pharmacology of endothelial nitric oxide synthase. *Ann Rev Pharmacol Toxicol*.;46:235–276.
- 32- **Egawa H, Kasahara M and Inomata Y(1999):** Long-term outcome of living related liver transplantation for patients with intrapulmonary shunting and strategy for complications. *Transplantation*.; 67: 712–717.
- 33- **Eisenhofer G, Aneman A, Hooper D. et al.(1996):** Mesenteric organ production, hepatic metabolism, and renal elimination of norepinephrine and its metabolites in humans. *J Neurochem*;66:1565–1573.
- 34- **Epstein SK, Zilberberg MA, Jacoby C, Ciubotaru RL, Kaplan LM. et al.(1998):**Response to symptom-limited exercise in patients with the hepatopulmonary syndrome. *Chest*; 114: 736–741.



References

- 35- **Faller M, Kessler R, Chaouat A, Ehrhart M, Petit H, Weitzenblum E. et al.(2000):** Platypnea-orthodeoxia syndrome related to an aortic aneurysm combined with an aneurysm of the atrial septum. *Chest*; 118: 553-557.
- 36- **Fallon MB, Abrams GA, Luo B, Hou Z, Dai J, Ku DD. et al.(1997):** The role of endothelial nitric oxide synthase in the pathogenesis of a rat model of hepatopulmonary syndrome. *Gastroenterology*;113: 606-614.
- 37- **Fallon MB, Mulligan DC, Gisch RG Krowka MJ. Et al.(2006):** Model for end-stage liver disease (MELD) exception for hepatopulmonary syndrome. *Liver Transpl*;12: 105-107.
- 38- **Fallon MB, Schiff ER, Sorrell MF, and Maddrey WC. and Arguedas MR. et al.(2007):**Pulmonary manifestations of liver disease: *Schiff's diseases of the liver*. 10th ed. Philadelphia, PA: Lippincott: Williams and Wilkins; 513-526.
- 39- **Fallon MB,and Arams GA.(2000):** Pulmonary Dysfunction in Chronic Liver Disease. *Hepatology*; 32:862.
- 40- **Farber HW,and Loscalzo J.** Pulmonary arterial hypertension. *N Engl J Med.*;351:1655–1665.
- 41- **Fernandez M, Mejias M, Garcia-Pras E, Mendez R, Garcia Pagan JC, Bosch J.(2007):** Reversal of portal hypertension and hyperdynamic planchnic circulation by combined vascular endothelial growth factor and platelet-derived growth factor blockade in rats. *Hepatology*;46:1208-1217.



References

- 42- **Fewtrell MS, Noble-Jamieson G and Revell S. (1994):** Intrapulmonary shunting in the biliary atresia / polysplenia syndrome: reversal after liver transplantation. *Arch Dis Child*; 70: 501–504.
- 43- **Flückiger M.(1884):** Vorkommen von trommelschlegelförmigen Fingerendphalangen ohne chronische Veränderungen an den Lungen oder am Herzen. *Wien Med Wochenschr*; 34:1457-1458.
- 44- **Freeman RB, Wiesner RH and Harper A. et al.(2002):** The new liver allocation system: moving towards evidence-based transplantation policy. *Liver Transpl*; 8:851-858.
- 45- **Gadour M O EH, Ayoola EA Yousef A Z et al.(2001):** Hepatopulmonary Syndrome .A review. *The Saudi Journal of Gastroenterology*; 7: 85-94.
- 46- **Garcia-Casasola G, Nacher J, Fernandez C, Guijarro C, Bilbao J, Zapatero A. et al.(2003):** Severe polycythemia as the first clinical presentation of hepato-pulmonary syndrome. *J Clin Gastroenterol*; 37: 89–91.
- 47- **Gómez FP, Barberà JA, Roca J, Burgos F, Gistau C, Rodriguez-Roisin R. et al.(2006):** Effects of nebulized N(G)-nitro-L-arginine methyl ester in patients with hepatopulmonary syndrome. *Hepatology*;43:1084-1091.
- 48- **Gómez FP, Martinez-Palli G, Barberà JA, Roca J, Navasa M, Rodriguez-Roisin R. et al.(2004):** Gas exchange mechanism of orthodeoxia in hepatopulmonary syndrome. *Hepatology*;40:660-666.



References

- 49- **Gomez R, Hallemans R, Mols P, et al.(2006)** :Hypoxic pulmonary vasocon-striction in liver cirrhosis. *Chest*;80:570–574.

- 50- **Gudavalli A, Kalaria VG, Chen X, Schwarz KQ. et al.(2002)**:Intrapulmonary arteriovenous shunt: diagnosis by saline contrast bubbles in the pulmonary veins. *J Am Soc Echocardiogr*;15:1012-1014.

- 51- **Halank M, Marx C, Usicenko S, Opitz C, Winkler J, Ewert R. et al.(2003)**: Inhaled iloprost for patients with portopulmonary hypertension. *Am J Respir Crit Care Med* 2003; 167: A277 (abstract).

- 52- **Hales MR.(1956)**: Multiple small arteriovenous fistulae of the lungs. *Am J Pathol*; 32:927-943.

- 53- **Henriksen JH, Gotz JP, Fuglsang S. et al.(2003)**: Increased circulating pro-brain natriuretic peptide (proBNP) and BNP in patients with cirrhosis: relation to cardiovascular dysfunction and severity of disease. *Gut*;52:1511–1517.

- 54- **Hess DT, Matsumoto A, Kim S-O, Marshall HE, Stamler JS. et al.(2005)**: Protein S-nitrosylation: purview and parameters. *Nat Rev Mol Cel Biol.*;6:150–166.

- 55- **Hira HS, Kumar J, Tyagi SK and Jain SK et al.(2003)**: A study of hepatopulmonary syndrome among patients of liver cirrhosis and portal hypertension. *Indian J Chest Dis Allied Sci*; 45: 165-171.



References

- 56- **Hobeika J, Houssin D, Bernard O, Devictor D, Grimon G, Chapuis Y. et al.(1994):** Orthotopic liver transplantation in children with chronic liver disease and severe hypoxemia. *Transplantation*; 57: 224-228.
- 57- **Hoepfer MM, Halank M, Mark C, et al.(2007):** Bosentan for treatment of portopulmonary hypertension. *Eur Respir J*; 30: 1096–1102.
- 58- **Hopkins WE, Waggoner AD, Barzilai B. et al.(1992):** Frequency and significance of intrapulmonary right-to-left shunting in end-stage hepatic disease. *Am J Cardiol*;70:516e9.
- 59- **Ian S.H. Cadden, Erica D. Greanya, Siegfried R. Erb. et al.(2009):** The use of sildenafil to treat portopulmonary hypertension prior to liver transplantation. *Annals of Hepatology*; April-June: 158-161.
- 60- **Irita K, Okamoto H, Sakaguchi Y.et al.(1998):** A possible increase in plasma norepinephrine by removal of the liver. *Acta Anaesthesiol Scand*;42:1164–1167.
- 61- **James MF, Hickman R, Janicki.et al.(1996):** Early effects of total hepatectomy on haemodynamic state and organ uptake of catecholamines in the pig. *Br J Anaesth*;76:713–720.
- 62- **Jensen DM, Pothamsetty S, Ganger D.et al.(1994):** Clinical manifestations of cirrhotic patients with intrapulmonary shunts. *Gastroenterology*;106:A912.



References

- 63- **Joshi D, Sizer E, Wendon J. et al.(2009):** High volumes of intrathoracic blood volume in hepatopulmonary syndrome. *Crit Care Resuscit*;11:129–131.

- 64- **Kamath PS, Wiesner RH and Malinchoc M.et al.(2001):** A model to predict survival in patients with end stage liver disease. *Hepatology*; 33:464-470.

- 65- **Kennedy TC and Knudson RJet al.(1977):** Exercise-aggravated hypoxemia and orthodeoxia in cirrhosis. *Chest*; 72: 305-309.

- 66- **Kim-Shapiro DB, Schechter AN, Gladwin MT.et al.(2006):**The reactions of nitric oxide, nitrite, and hemoglobin in physiology and therapeutics. *Arterioscler Thromb Vasc Biol.*;26:697–705.

- 67- **Krowka MJ and Cortese DA. et al (2008):** Severe hypoxemia associated with liver disease: Mayo Clinic experience and the experimental use of almitrine bismesylate. *Mayo Clin Proc*; 62: 164–173.

- 68- **Krowka MJ, Cortese DA. et al.(1990):** Hepatopulmonary syndrome: an evolving perspective in the era of liver transplantation. *Hepatology*;11:138-141.

- 69- **Krowka MJ, Cortese DA.et al.(1987):** Severe Hypoxemia associated with liver disease: Mayo Clinic experience and the experimental use of almitrine bismesylate. *Mayo Clin Proc*;62:164-173



References

- 70- **Krowka MJ, Frantz RP, McGoon MD, Severson C, Plevak DJ, Wiesner RH. et al.(1999):** Improvement in pulmonary hemodynamics during intravenous epoprostenol (prostacyclin): *Hepatology*; 30: 641–648.
- 71- **Krowka MJ, Mandell MS, Ramsay MAE. et al.(2004):** Hepatopulmonary syndrome and portopulmonary hypertension: a report of the multicenter liver transplant database. *Liver Transpl*;10:174–182.
- 72- **Krowka MJ, Plevak DJ, Findlay JY, Rosen CB, Wiesner RH, Krom RA. et al.(2000):** Pulmonary hemodynamics and perioperative cardiopulmonary- related mortality in patients with portopulmonary hypertension undergoing liver transplantation. *Liver Transpl*;6:443–450.
- 73- **Krowka MJ, Porayko MK and Plevak DJ. et al.(1997):** Hepatopulmonary syndrome with progressive hypoxemia as an indication for liver transplantation: case reports and literature review. *Mayo Clin Proc*; 72: 44–53.
- 74- **Krowka MJ, Tajik AJ, Dickson ER. et al.(1990):** Intrapulmonary vascular dilatations (IPVD) in liver transplant candidates. Screening by two-dimensional contrast-enhanced echocardiography. *Chest*; 97: 1165–1170.
- 75- **Krowka MJ.(2000):** Hepatopulmonary syndromes. *Gut* 2000; 46: 1– 4.
- 76- **Krowka MJ.(2005)** Hepatopulmonary Syndrome and Portopulmonary Hypertension: Implications for Liver Transplantation. *Clin Chest Med* 26; 587 – 597.



References

- 77- **Lange PA and Stoller JK.(1995):** The hepatopulmonary syndrome. *Ann Intern Med*; 122: 521–529.
- 78- **Lange PA and Stoller JK. (1996):** The hepatopulmonary syndrome: effect of liver transplantation. *Clin Chest Med*; 17(1): 115-124.
- 79- **Lee D and Lepler L.(1999):** Severe intrapulmonary shunting associated with metastatic carcinoid. *Chest*; 115:1203-1207.
- 80- **Lee JM, Choi MS and Lee SC. et al.(2002)::** prevalence and risk factors of significant intrapulmonary shunt in cirrhotic patients awaiting liver transplantation. *Korean J Hepatol*; 8: 271-276.
- 81- **Lee KN, Lee HJ, Shin WW, Webb WR. et al.(1999):** Hypoxemia and liver cirrhosis (hepatopulmonary syndrome) in eight patients: comparison of the central and peripheral pulmonary vasculature. *Radiology*; 211: 549–553.
- 82- **Leung AN.(2003)** Case 63: Hepatopulmonary Syndrome. *Radiology*;229:64-67.
- 83- **Lucey MR, Brown KA and Everson GT. et al.(1997):** Minimal criteria for placement of adults on the liver transplant waiting list. *Liver Transpl surg*; 3: 628-637.
- 84- **Luo B, Abrams GA, Fallon MB. et al.(1998):** Endothelin-1 in the rat bile duct ligation model of hepatopulmonary syndrome: correlation with pulmonary dysfunction. *J Hepatol*; 29: 571– 578.
- 85- **Luo B, Tang L, Ling Y. et al.(2002):** Increased pulmonary vascular endothelin-B receptor expression in cirrhotic and portal hypertensive



References

rats: a potential mechanism in experimental hepatopulmonary syndrome. *Hepatology*; 36: 320A.

- 86- **Malinchoc M, Kamath PS and Gordon FD. et al.(2000):** A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts. *Hepatology*; 31:864-871.
- 87- **Mandell MS.** Portopulmonary hypertension. *Liver Transpl* 2000; 6: 36–43.
- 88- **Martinez G, Barbera JA, Navasa M, Roca J, Visa J, Rodriguez-Roisin R. et al.(1999):** Hepatopulmonary syndrome associated with cardiorespiratory disease. *J Hepatol*; 30: 882–889.
- 89- **Martinez-Palli G, Barberà J, Visa J. et al.(1996):**Hepatopulmonary syndrome: Prevalence and clinical markers. *Eur Respir J*;9:179.
- 90- **Matthew P. Coggins, Kenneth D. et al. (2007):**Nitric Oxide in the Pulmonary Vasculature *Arterioscler. Thromb. Vasc. Biol.*;27:1877-1885.
- 91- **Mc Mahon TJ, Moon RE, Luschinger BP, Carraway MS, Stone AE, Stolp BW, Gow AJ, Pawloski JR, Watke P, Singel DJ, Piantadosi CA, Stamler JS. et al.(2002):** Nitric oxide in the human respiratory cycle. *Nat Med.*;8:711–717.
- 92- **McDiarmid SV, Walker WA, Durie PR, Hamilton JR, Walker-Smith SA and Watkins JB. et al.(2000):** Treatment of end stage liver disease. *Pediatric Gastrointestinal Disease*, 3rd ed.; 1264-1265.



References

- 93- **Mohammad Alizadeh AH, Fatemi SR, Mirzaee V, Khoshbaten M, Talebipour B, Sharifi an A, Khoram Z, Haj-sheikh-oleslami F, Gholamreza-shirazi M, Zali MR. et al.(2006):** Clinical features of hepatopulmonary syndrome in cirrhotic patients. *World J Gastroenterol*; 12: 1954-1956.
- 94- **Moller S, Krag A, Henriksen JH and Bendtsen F. et al.(2007):**Pathophysiological aspects of pulmonary complications of cirrhosis. *Scand JGastroenterol*;42:419-427.
- 95- **Moustafa Y, Farrag M, Zolfakar TS, Khater AA and Hussein EA. et al.(2007):** Determinants of hypoxemia in liver cirrhosis: effects of hypoxemia on left ventricular functions and QTc interval in liver cirrhotic patients, *The Egyptian Journal of Chest Diseases and Tuberculosis* 53;3,4:236-246.
- 96- **Munzel T, Feil R, Mulsch A, Lohmann SM, Hofmann F, Walter U. et al.(2003):** Physiology and pathophysiology of vascular signaling controlled by cyclic guanosine 3,5-cyclic monophosphate-dependent protein kinase. *Circulation.*;108:2172–2183.
- 97- **Murray KR, Carithers RL Jr. et al.(2005):** AASLD practice guidelines: evaluation of the patient for liver transplantation. *Hepatology*;41:1407–1432.
- 98- **Murtaugh PA, Dickson ER and Van Dam GM. Rt al.(1994):** Primary biliary cirrhosis: prediction of short-term survival based on repeated patient visits. *Hepatology*; 20: 126-134.



References

- 99- **Naeije R.(2003):** Hepatopulmonary syndrome and portopulmonary hypertension.; 133: 163–69.
- 100-**Naeije R, Dinh-Xuan AT.et al.(2005):**The hepatopulmonary syndrome: NO way out? Eur Respir J; 25:212.
- 101-**Nakos G, Evrenoglou D, Vassilakis N, Lampropoulos S. et al.(1993):** Haemodynamics and gas exchange in liver cirrhosis: the effect of orally administered almitrine bismesylate. Respir Med;87:93-98.
- 102-**Orfanos SE, Armaganidis A, Glynos C, Psevdi E, Kaltsas P, Sarafidou P, Catravas JD, Dafni UG, Langleben D, Roussos C. et al.(2000):** Pulmonary capillary endothelium-bound angiotensin converting enzyme activity in acute lung injury. Circulation; 102:2011–2018.
- 103-**Pilatis ND, Jacobs LE, Rekpattanappipat P. et al.(2000):**Clinical predictors of pulmonary hypertension in patients undergoing liver transplantation. Liver Transpl;6:85–91.
- 104-**Poterucha JJ, Krowka MJ, Dickson ER, Cortese DA, Stanson AW and Krom RAF. et al.(1995):** Failure of hepatopulmonary syndrome to resolve after liver transplantation and successful treatment with embolotherapy. *Hepatology*; 21: 96–100.
- 105-**Rabiller A, Nunes H, Lebrec D. et al.(2002):**Prevention of gram-negative translocation reduces the severity of hepatopulmonary syndrome. Am J Respir Crit Care Med;166:514-517.



References

- 106-**Rafaran AL, Maurer J, Metha AC, Schilz R. et al.(2000):** Progressive portopulmonary hypertension after liver transplantation treated with epoprostenol. *Chest*; 118: 1497–1500.
- 107-**Raffy O, Sleiman C, Vachiery F. Et al.(1996):** Refractory hypoxemia during liver cirrhosis: hepatopulmonary syndrome or "primary" pulmonary hypertension. *Am J Respir Crit Care Med*; 153: 1160–1171.
- 108- **Ramsay MAE, Spikes C, East CA. et al.(2000):** The perioperative management of portopulmonary hypertension with nitric oxide and epoprostenol. *Anesthesiology*; 90: 299–301.
- 109-**Regev A, Yeshurun M and Rodriguez M. et al.(2001):** Transient hepatopulmonary syndrome in a patient with acute hepatitis A. *J Viral Hepat*;8:83-86.
- 110-**Reichenberger F, VoswinckelR, Steveling E. et al.(2006):** Sildenafil treatment for portopulmonary hypertension. *Eur Respir J*;28:563–567.
- 111-**Ribas J, Angrill J, Barbera` JA. et al.(1999):** Isosorbide-5-mononitrate in the treatment of pulmonary hypertension associated with portal hypertension. *Eur Respir J*; 13: 210–212.
- 112-**Rich S, Kaufmann E, Levy PS. et al.(1992):** The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. *N Engl J Med*; 327:76–81.



References

- 113-**Robert Naeije, Serge Brimiouille. et al.(2001):** Importance of hypoxic pulmonary vasoconstriction in maintaining arterial oxygenation during acute respiratory failure. *Physiology in medicine.*; 5:67-71.
- 114-**Roberts KE, Kawut SM, Krowka MJ, Brown RS Jr, Trotter JF, Shah V, Peter I, Tighiouart H, Mitra N, Handorf E, Knowles JA, Zacks S and Fallon MB. et al.(2010):** Pulmonary Vascular Complications of Liver Disease Study Group. Genetic risk factors for hepatopulmonary syndrome in patients with advanced liver disease. *Gastroenterology.* Jul;139(1):130-9.e24. Epub 2010 Mar 24.
- 115-**Rodriguez-Roisin R, Agustí AGN, Roca J. et al.(1992):** The hepatopulmonary syndrome: new name, old complexities. *Thorax*; 47: 897–902.
- 116-**Rodriguez-Roisin R, Krowka MJ, Hervé P, Fallon MB. et al.(2004):** Pulmonary-hepatic vascular disorders (PHD). *Eur Respir J*;24:861- 880.
- 117-**Rodríguez-Roisin R, Krowka MJ. et al.(2008):** Hepatopulmonary syndrome - a liver-induced lung vascular disorder. *N Engl J Med*;358:2378-2387.
- 118-**Rodriguez-Roisin R, Roca J, Agustí AGN, Mastai R, Wagner PD, Bosch J. et al.(1987):** Gas exchange and pulmonary vascular reactivity in patients with liver cirrhosis. *Am Rev Respir Dis*; 135: 1085–1092.
- 119-**Rohit Budhiraja, Paul M. Hassoun. et al.(2003):**Portopulmonary Hypertension. *Chest*;123;562-576.



References

- 120-**Rolla G, Brussino L, Colagrande P. et al.(1997):**Exhaled nitric oxide and oxygenation abnormalities in hepatic cirrhosis. *Hepatology*; 26: 842–847.
- 121-**Rolla G, Bucca C, Brussino L. et al.(1994):**Methylene blue in the hepatopulmonary syndrome. *N Eng J Med*;331:1098.
- 122-**Rolla'n M J, Muñoz A C, Pe´rez T, Bratos JL. et al.(2006):** Value of contrast echocardiography for the diagnosis of hepatopulmonary syndrome. *The European Society of Cardiology*;408-410.
- 123-**Rovin B, Lu L and Saxena R. et al.(1999):** A novel polymorphism in the MCP-1 gene regulatory region that influences MCP-1 expression. *Biochem Biophys Res Commun*; 34:259-344.
- 124-**Rydell R and Hoffbauer FW.(1956):** Multiple pulmonary arteriovenous fistulas in juvenile cirrhosis. *Am J Med*;21:450-460.
- 125-**Ryning A, Schrumpf E and Abdelnoor M. et al.(1990):** Factors of prognostic importance in primary biliary cirrhosis. *Scand J Gastroenterol*; 25:119-126.
- 126-**Salvi SS.(1999):** Alpha1-adrenergic hypothesis for pulmonary hypertension. *Chest*; 115: 1708– 1719.
- 127-**Salvi SS.(2000):** Liver disease and pulmonary hypertension. *Gut*;47:595–600.
- 128-**Sauzeau V, Le Jeune H, Cario-Toumaniantz C, Smolenski A, Lohmann SM, Bertoglio J, Chardin P, Pacaud P, Loirand G. et**



References

- al.(2000):** Cyclic GMPdependent protein kinase signaling pathway inhibits RhoA-induced Ca²sensitization of contraction in vascular smooth muscle. *J Biol Chem.*; 275:21722–21729.
- 129-**Schenk P, Fuhrmann V, Madl C. et al.(2002):** Hepato-pulmonary syndrome: prevalence and predictive value of various cut offs for arterial oxygenation and their clinical consequences. *Gut*; 51: 853–859.
- 130-**Schenk P, Madl C, Rezale-Majd S, Lehr S, Muller C. et al.(2000):** Methylene blue improves the hepatopulmonary syndrome. *Ann Intern Med*; 133: 701–706.
- 131-**Schenk P, Schö niger-Hekele M, Furrmann V, Madl C, Silberhumer G, Müller C. et al.(2003):**Prognostic significance of the hepatopulmonary syndrome in patients with cirrhosis. *Gastroenterology*; 125: 1042–1052.
- 132-**Schwartz SM and Pound DC. et al.(1992):** Hepatopulmonary syndrome: failure of response to somatostatin analogue. *Gastroenterology*; 882A.
- 133-**Shaul PW, North AJ, Brannon TS, Ujiie K, Wells LB, Nisen PA, Lowenstein CJ, Snyder SH, Star RA. et al.(1995):** Prolonged in vivo hypoxia enhances nitric oxide synthase type I and type III gene expression in adult rat lung. *Am J Respir Cell Mol Biol.*;13:167–174.
- 134-**Shetty K, Rybiki L and Carry WD. et al.(1997):** The Child-Pugh classification as a prognostic indicator for survival in primary sclerosing cholangitis. *Hepatology*; 25: 1049-1053.



References

- 135-**Singel DJ, Stamler JS. et al.(2005):** Chemical physiology of blood flow regulation by red blood cells. *Ann Rev Physiol.*; 67: 99 –145.
- 136-**Song JY, Choi JY, Ko JT, Bae EJ, Kim HS, Noh CI, Yoon YS. et al.(1996):** Long-term aspirin therapy for hepatopulmonary syndrome. *Pediatrics*;97(6 Pt 1):917-920.
- 137-**Starkel P, Vera A, Gunson B, Mutimer D. et al.(2002):**Outcome of liver transplantation for patients with pulmonary hypertension. *Liver Transpl*; 8: 382–388.
- 138-**Stoller JK, Lange PA, Westveer MK. et al.(1995):** Prevalence and reversibility of the hepatopulmonary syndrome after liver transplantation. The Cleveland Clinic experience. *West J Med*;163:133–138.
- 139-**Swanson KL, Krowka MJ. et al.(2002):** Arterial oxygenation associated with portopulmonary hypertension. *Chest* 2002; 121: 1869–1875.
- 140-**Swanson KL, Wiesner RH, Krowka MJ. et al.(2005):**Natural history of hepatopulmonary syndrome: impact of liver transplantation. *Hepatology*;41:1122-1129.
- 141-**Sztrymf B, Rabiller A, Nunes H. et al.(2004):** Prevention of hepatopulmonary syndrome and hyperdynamic state by pentoxifylline in cirrhotic rats. *Eur Respir J*;23:752-758.



References

- 142-**Tieppo J, Vercelino R, Dias AS, Marroni CA, Marroni N: et al.(2005):** Common bile duct ligation as a model of hepatopulmonary syndrome and oxidative stress. *Arq Gastroenterol*;42:238-244.
- 143-**Tzovaras N, Stefos A and Georgiadou SP. et al.(2006):** Reversion of severe hepatopulmonary syndrome in a non cirrhotic patient after corticosteroid treatment for granulomatous hepatitis: A case report and review of the literature. *World J Gastroenterol*; 12: 336-339.
- 144-**Umeda N, Kamath PS. et al.(2009):**Hepatopulmonary syndrome and portopulmonary hypertension. *Hepatol Res*;39:1020-1022.
- 145-**Van der Linden P, Le Moine O, Ghysels M, Ortinez M, Deviere J. et al.(1996):**Pulmonary hypertension after transjugular intrahepatic portosystemic shunt: effects on right ventricular function. *Hepatology*; 23: 982–987.
- 146-**Vedrinne JM, Duperret S, Bizollon T. et al.(1997):** Comparison of transesophageal and transthoracic contrast echocardiography for detection of an intrapulmonary shunt in liver disease. *Chest*;111:1236–1240.
- 147-**Wagner PD.(1995):** Impairment of gas exchange in liver cirrhosis. *Eur Respir J*; 8: 1993–1995.
- 148-**Weir EK, Archer SL. et al.(1995):** The mechanism of acute hypoxic pulmonary vasoconstriction: the tale of two channels. *FASEB J*, 9:183–189.



References

- 149-**Whyte MK, Hughes JM, Peters AM, Ussov W, Patel SBurroughs AK. et al.(1998):** Analysis of intrapulmonary right to left shunt in the hepatopulmonary syndrome. *J Hepatol*; 29: 85–93.
- 150-**Wiesner RH, Edwards EB and Freeman RB. Et al.(2003):** Model for end stage liver disease (MELD) and allocation of donor livers. *Gastroenterology*; 124:91-96.
- 151-**Wolfe JD, Tashkin DP, Holly FE, Brachman MB, Genovesi MG. et al.(1997):** Detection of abnormal small pulmonary vascular channels by a quantitative radionuclide method. *Am J Med*, 63:746-754.
- 152-**Yeshua H, Blendis LM and Oren R. et al.(2009):** Pulmonary manifestations of liver disease. *Semin Cardiothorac Vasc Anesth*;13:60–69.
- 153-**Zamanian Roham T, Francois Haddad, Ramona L. Doyle, Ann B. Weinacker. et al.(2007):** Management strategies for patients with pulmonary hypertension in the intensive care unit *Crit Care Med* Vol. 35, No. 9.
- 154-**Zhang HY, Han de W, Su AR, Zhang LT, Zhao ZF, Ji JQ, et al.(2007):** Intestinal endotoxemia plays a central role in development of hepatopulmonary syndrome in a cirrhotic rat model induced by multiple pathogenic factors. *World J astroenterol*;13:6385-6395.



References

- 155-**Zhang J, Ling Y, Luo B.(2003)** Analysis of pulmonary heme oxygenase-1 and nitric oxide synthase alterations in experimental hepatopulmonary syndrome. *Gastroenterology*;125:1441-1451.
- 156-**Zhang J, Ling Y, Tang L, Luo B, Pollock DM, Fallen MB,et al.(2009):** Attenuation of experimental hepatopulmonary syndrome in endothelin B receptor-deficient rats. *Am J Physiol Gastrointest Liver Physiol*; 296: 704-708.
- 157-**Zhang J, Ling Y, Tang L.(2007):** Pentoxifylline attenuation of experimental hepatopulmonary syndrome. *J Appl Physiol*; 102:949-955.
- 158-**Zhang J, Luo B, Tang L, et al.(2009):** Pulmonary angiogenesis in a rat model of hepatopulmonary syndrome. *Gastroenterology*; 136:1070–1080.